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Abstract
Background: The distinction between right-sided and left-sided colon cancer has recently received considerable
attention due to differences regarding underlying genetic mutations. There is an ongoing debate if right- versus
left-sided tumor location itself represents an independent prognostic factor. We aimed to investigate this question
by using propensity score matching.
Methods: Patients with resected, stage I - III colon cancer were identified from the Surveillance, Epidemiology, and
End Results (SEER) database (2004–2012). Both univariable and multivariable Cox regression as well as propensity score
matching were used.
Results: Overall, 91,416 patients (51,937 [56.8 %] with right-sided, 39,479 [43.2 %] with left-sided colon cancer; median
follow-up 38 months) were eligible. In univariable analysis, patients with right-sided cancer had worse overall (hazard
ratio [HR] = 1.32, 95 % CI:1.29–1.36, P < 0.001) and cancer-specific survival (HR = 1.26, 95 % CI:1.21–1.30, P < 0.001)
compared to patients with left-sided cancer. After propensity score matching, the prognosis of right-sided carcinomas
was better regarding overall (HR = 0.92, 95 % CI: 0.89 − 0.94, P < 0.001) and cancer-specific survival (HR = 0.90, 95 % CI:0.
87 − 0.93, P < 0.001). In stage I and II, the prognosis of right-sided cancer was better for overall (HR = 0.89, 95 % CI:0.84–0.
94 and HR = 0.85, 95 % CI:0.81–0.89) and cancer-specific survival (HR = 0.71, 95 % CI:0.64 − 0.79 and HR = 0.75, 95 % CI:0.
70–0.80). Right- and left-sided colon cancer had a similar prognosis for stage III (overall: HR = 0.99, 95 % CI:0.95–1.03 and
cancer-specific: HR = 1.04, 95 % CI:0.99–1.09).
Conclusions: This population-based analysis on stage I - III colon cancer provides evidence that the prognosis of
localized right-sided colon cancer is better compared to left-sided colon cancer. This questions the paradigm from
previous research claiming a worse survival in right-sided colon cancer patients.
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Background
Colorectal cancer is one of the most commonly diag-
nosed cancers worldwide. The incidence is estimated to
be 1.2 million per annum, and more than 600 000 pa-
tients die from this cancer every year [1, 2], hence repre-
senting a relevant public health problem. Over the past
years, the distinction between right-sided and left-sided
colon cancer has been brought into focus due to several
reasons: Recent studies have revealed an increased fre-
quency of right-sided colon cancer over the past decade
[3, 4], which prompted the investigation for potential
reasons of variation by anatomic sites. As shown by a re-
cent systematic review, many publications pointed out
several differences between right-sided and left-sided
colon cancer regarding epidemiology, clinical presenta-
tion, pathology, and genetic mutations [5]. It has been
shown that patients with right-sided colon cancer were
older, more often female, had more advanced tumor
stages, increased tumor sizes, more often poorly dif-
ferentiated tumors, and different molecular biological
tumor patterns [4, 6–13].
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Data regarding prognosis in right-sided versus left-
sided colon cancer are conflicting, and it remains a mat-
ter of great debate whether tumor location itself has a
significant prognostic impact. The majority of studies
demonstrated a poorer survival in right-sided compared
to left-sided colon cancer [14–18]. In contrast to those
data, Weiss et al. [19] found no overall difference in
5-year mortality between right- and left-sided colon
cancer after adjusting for various variables.
The objective of the present population analysis of
91,416 colon cancer patients from the Surveillance,
Epidemiology, and End Results (SEER) Program was to
compare overall and cancer-specific survival between
two large, virtually identical groups of patients with
right- and left-sided colon cancer using propensity-score
matching.
Methods
Cohort definition: surveillance, epidemiology, and end
results
Data from the Surveillance, Epidemiology, and End
Results (SEER) Program of the National Cancer Institute
in the United States, covering approximately 28 % of
cancer cases in the United States were used for the
present population-based analysis [20]. SEER data were
collected and reported using data items and codes as doc-
umented by the North American Association of Central
Cancer Registries (NAACCR) [21]. Primary cancer site
and histology were coded according to criteria in the third
edition of the International Classification of Diseases for
Oncology (ICD-O-3) and used to identify 246,390 pa-
tients with colon cancer diagnosed between 2004 and
2012 [22]. Patients with cancer of the cecum and as-
cending colon were accounted for right-sided colon
cancer and patients with cancer of the descending or
sigmoid colon were accounted for left-sided colon
cancer. Patients with cancer on other or unknown lo-
cation of the cancer were excluded. Figure 1 depicts
the selection process leaving 51,937 patients with
right-sided and 39,479 patients with left-sided colon
cancer for analysis.
Statistical analysis
Statistical analyses were performed using the R statistical
software (www.r-project.org). A two-sided p-value <0.05
was considered statistically significant. Chi-Square statis-
tics were used to analyze proportions. After descriptive
analysis, the impact of location of colon cancer (right-
sided versus left-sided) on overall and cancer-specific
survival was assessed by Cox regression analysis with
and without risk-adjustment for tumor stage, T-stage, re-
trieval and positivity of regional lymph nodes, grading,
histology, preoperative serum carcinoembryonic antigen
(CEA), type of operation, year of diagnosis, age, gender,
ethnicity, and marital status (risk set). Additionally, a
backward variable selection procedure from the full Cox
regression model based on the Akaike’s information
criterion was performed. The proportional hazard as-
sumption was tested by scaled Schoenfeld residuals and
by inspection of the hazard ratio (HR) plots [23]. The
imbalances regarding prognostic factors between pa-
tients with right-sided and left-sided colon cancer were
assessed by multivariable logistic regression. To further
adjust for these differences in baseline characteristics
and hence further minimizing bias, a propensity score
matched analysis was performed as a further statistical
method for adjustment [24–26] using the “MatchIt” R
package [27]. The propensity score matching was per-
formed as a full bipartite weighting matching procedure
[28] with stratification for year of diagnosis and tumor
stage. In this procedure, each patient with left-sided
colon cancer was matched to all possible patients with
right-sided colon cancer, forming subclasses and assign-
ing weights such that within each subclass both groups
have similar covariate values. Patients with right-sided
colon cancer without a counterpart among the patients
with left-sided colon cancer and vice versa were ex-
cluded from this analysis. A multivariable logistic regres-
sion conditional on the subgroups obtained by the
matching procedure was performed to assess the persist-
ing bias. Thereafter, overall and cancer-specific survival
in patients with right-sided and left-sided colon cancer
were assessed in a Cox regression analysis using the
weights and strata obtained by the matching propensity
score analysis. Finally, the propensity score matching
procedure was repeated separately for stage I, II, and III
colon cancer.
Results
Patient characteristics
For the present investigation 91,416 of 246,390 patients di-
agnosed with colon cancer between 2004 and 2012 were in-
cluded (Fig. 1). The mean follow up was 42.3 ± 30.5 months
and the median follow-up was 38 months (IQR: 16 to
66 months). At the end of follow-up period, 66,082 (72.3 %)
patients were alive, 13,507 (14.8 %) died from colon cancer
and 11,827 (12.9 %) died due to other reasons.
Overall, 51,937 (56.8 %) patients had right-sided colon
cancer including 27,548 (30.1 %) patients with cancer of
the cecum and 24,389 (26.7 %) patients with cancer of
the ascending colon. Left-sided colon cancer was diag-
nosed in 39,479 (43.2 %) patients including 7039 (7.7 %)
patients with cancer of the descending colon and 32,440
(35.5 %) patients with cancer of the sigmoid colon.
Table 1 compares the patients’ characteristics for the two
groups indicating relevant imbalances for all patients’
characteristics except for CEA-stage (P = 0.187). Patients
with right-sided colon cancer had more advanced tumor
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Fig. 1 (See legend on next page.)
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stages, higher T-stages, had more regional lymph nodes
retrieved, a higher grading, more often mucinous carcin-
omas, were more often Caucasian or African-American,
were older, less often married, and were more often fe-
male (all P < 0.001).
Impact of cancer location on survival
The observed 5-year overall survival rate for patients
with right-sided colon cancer was 65.1 % (95 % CI: 64.6
to 65.6 %) compared with 72.1 % (95 % CI: 71.5 to 72.6 %)
for patients with left-sided colon cancer. The 5-year
cancer-specific survival rate for patients with right-sided
colon cancer was 79.8 % (95 % CI: 79.4 to 80.2 %) com-
pared with 82.9 (95 % CI: 82.5 to 83.4 %) for patients with
left-sided colon cancer (Fig. 2). Table 2 depicts the
prognostic value of cancer side and the other patient’s
characteristics on adjusted and unadjusted overall and
cancer-specific mortality. In unadjusted analysis, right-
sided colon cancer was associated with a significantly in-
creased risk of overall mortality (hazard ratio of death
[HR] = 1.32, 95 % CI: 1.29 to 1.36, P < 0.001) and cancer-
specific mortality (HR = 1.26, 95 % CI: 1.21 to 1.30,
P < 0.001). After multivariable adjustment, patients with
right-sided colon cancer had a significantly worse overall
(HR = 1.05, 95 % CI: 1.02 to 1.09, P < 0.001) but a similar
cancer-specific survival (HR = 1.03, 95 % CI: 0.99 to 1.08,
P = 0.156) compared to patients with left-sided colon can-
cer. A backward variable selection procedure from the full
Cox regression model confirmed a significantly increased
risk for overall (HR = 1.05, 95 % CI: 1.02 to 1.09, P <
0.001) but not for cancer-specific mortality.
Adjusting for patients characteristics with propensity
score matching
To further assess whether the colon cancer location has
an independent prognostic impact on survival, a bipart-
ite propensity score matching analysis with stratification
for stage and year of diagnosis was performed. The ra-
tionale for this analysis were the significant imbalances
of baseline characteristics in multivariable logistic re-
gression between patients with left- and right-sided
colon cancer for all confounders (P < 0.001) except for
the year of diagnosis (P = 0.285) and the marital status
(P = 0.877, Table 3).
Before the matching procedure, the propensity score for
patients with left-sided colon cancer was 0.346 ± 0.268
compared to 0.739 ± 0.220 in patients with right-sided
colon cancer (P < 0.001), thus indicating a strong and
clinically relevant bias regarding the observed patient and
tumor characteristics in the two groups. After the
matching procedure, the propensity score was virtually
the same in the two groups (0.738 ± 0.220 compared to
0.739 ± 0.220, P = 0.622), thus indicating no persisting
relevant bias regarding the observed characteristics in the
two groups (Table 3). Of the entire cohort, 1349 patients
were excluded enabling a propensity score matching in
the remaining 90,067 patients. In this cohort, the prognosis
of right-sided colon cancer was slightly better compared to
left-sided colon cancer regarding overall (HR = 0.92, 95 %
CI: 0.89 to 0.94, P < 0.001) and cancer-specific mortality
(HR = 0.90, 95 % CI: 0.87 − 0.93, P < 0.001). The 5-year
overall survival rate for patients with right-sided colon can-
cer was 65.5 % (95 % CI: 65.0 to 66.0 %) compared with
63.0 % (95 % CI: 62.5 to 63.6 %) for patients with left-sided
colon cancer. The 5-year cancer-specific survival rate for
patients with right-sided colon cancer was 79.8 % (95 % CI:
79.4 to 80.2 %) compared with 77.8 % (95 % CI: 77.3 to
78.3 %) for patients with left-sided colon cancer.
Stratified stage-wise analysis
Motivated by an unsuspected better survival in right-
sided cancer, a propensity score matched analysis was
performed for each stage individually confirming a better
prognosis for stage I and II right-sided colon cancer
(Fig. 3). In the stage I subgroup, the prognosis of
right -sided colon cancer was better regarding overall
(HR = 0.89, 95 % CI: 0.84–0.94, P < 0.001)) and
cancer-specific survival (HR = 0.71, 95 % CI: 0.64–0.79,
P < 0.001)). In the stage II subgroup, the prognosis of
right- sided colon cancer was better regarding overall
(HR = 0.85, 95 % CI: 0.81–0.89, P < 0.001) and
cancer-specific survival (HR = 0.75, 95 % CI: 0.70 to
0.80, P < 0.001). In the stage III subgroup, the prognosis
of right- and left-sided colon cancer was similar regarding
overall (HR = 0.99, 95 % CI: 0.95–1.03, P = 0.497) and
cancer-specific survival (HR = 1.04, 95 % CI: 0.99–1.09,
P = 0.129).
The overall five year survival rates for right-sided
cancers in stage I, II, and III were 77.4 % (95 % CI: 76.6
to 78.2 %) 68.3 % (95 % CI: 67.6 to 69.1 %), and 53.3 %
(95 % CI: 52.5 to 54.2 %) compared to 74.9 % (95 % CI:
74 to 75.8 %), 63.9 % (95 % CI: 63 to 64.8 %), and 52.9 %
(95 % CI: 51.9 to 53.8 %) in left-sided carcinomas. The
cancer-specific survival rates for right-sided cancers in
(See figure on previous page.)
Fig. 1 Flow chart of patients’ cohort definition. Data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer
Institute in the United States, covering approximately 28 % of cancer cases in the United States were used for the present population-based
analysis. Primary cancer site and histology were coded according to criteria in the third edition of the International Classification of Diseases for
Oncology (ICD-O-3) and used to identify 246,390 patients with colon cancer diagnosed between 2004 and 2012. The figure shows the selection
process leaving 51,937 patients with right-sided and 39,479 patients with left-sided colon cancer for analysis
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Table 1 Patient characteristics
Patient characteristics
Total Right-sided carcinoma Left-sided carcinoma Pa
N = 91,416 N = 51,937 N = 39,479
Tumor stage Stage I 25,482 (27.9 %) 13,864 (26.7 %) 11,618 (29.4 %) <0.001
(AJCC 6th ed.) Stage II 33,323 (36.5 %) 19,965 (38.4 %) 13,358 (33.8 %)
Stage III 32,611 (35.7 %) 18,108 (34.9 %) 14,503 (36.7 %)
T-stage T1 14,110 (15.4 %) 6415 (12.4 %) 7695 (19.5 %) <0.001
T2 15,873 (17.4 %) 9580 (18.4 %) 6293 (15.9 %)
T3 51,416 (56.2 %) 29,980 (57.7 %) 21,436 (54.3 %)
T4 10,017 (11.0 %) 5962 (11.5 %) 4055 (10.3 %)
Number of positive 0 58,805 (64.3 %) 33,829 (65.1 %) 24,976 (63.3 %) <0.001
regional lymph nodes 1 10,557 (11.5 %) 5627 (10.8 %) 4930 (12.5 %)
2–3 10,531 (11.5 %) 5672 (10.9 %) 4859 (12.3 %)
4–6 6560 (7.2 %) 3692 (7.1 %) 2868 (7.3 %)
7+ 4963 (5.4 %) 3117 (6.0 %) 1846 (4.7 %)
Number of retrieved <12 lymph nodes 24,256 (26.5 %) 10,243 (19.7 %) 14,013 (35.5 %) <0.001
regional lymph nodes 12–16 lymph nodes 26,123 (28.6 %) 14,917 (28.7 %) 11,206 (28.4 %)
17+ lymph nodes 41,037 (44.9 %) 26,777 (51.6 %) 14,260 (36.1 %)
Grading G1 8568 (9.4 %) 4721 (9.1 %) 3847 (9.7 %) <0.001
G2 64,221 (70.3 %) 34,812 (67.0 %) 29,409 (74.5 %)
G3 14,228 (15.6 %) 9886 (19.0 %) 4342 (11.0 %)
G4 1490 (1.6 %) 1099 (2.1 %) 391 (1.0 %)
Unknown 2909 (3.2 %) 1419 (2.7 %) 1490 (3.8 %)
Histology Adenocarcinoma 64,760 (70.8 %) 35,637 (68.6 %) 29,123 (73.8 %) <0.001
Adeno-Ca in adenomatous polyp 6791 (7.4 %) 2885 (5.6 %) 3906 (9.9 %)
Adeno-Ca in villous adenoma 2646 (2.9 %) 1721 (3.3 %) 925 (2.3 %)
Adeno-Ca in tubulovillous adenoma 8142 (8.9 %) 4897 (9.4 %) 3245 (8.2 %)
Mucinous carcinoma 9077 (9.9 %) 6797 (13.1 %) 2280 (5.8 %)
CEA C0-stage 32,999 (36.1 %) 18,679 (36.0 %) 14,320 (36.3 %) 0.185
C1-stage 17,232 (18.9 %) 9896 (19.1 %) 7336 (18.6 %)
Unknown/Borderline 41,185 (45.1 %) 23,362 (45.0 %) 17,823 (45.1 %)
Operation Segmental resection 36,201 (39.6 %) 7750 (14.9 %) 28,451 (72.1 %) <0.001
Hemi/subtotal colectomy 54,241 (59.3 %) 43,777 (84.3 %) 10,464 (26.5 %)
Other 974 (1.1 %) 410 (0.8 %) 564 (1.4 %)
Year 2004 to 2006 31,514 (34.5 %) 17,703 (34.1 %) 13,811 (35.0 %) 0.005
2007 to 2009 31,314 (34.3 %) 17,798 (34.3 %) 13,516 (34.2 %)
2010 to 2012 28,588 (31.3 %) 16,436 (31.6 %) 12,152 (30.8 %)
Age Up to 49 years 8015 (8.8 %) 3175 (6.1 %) 4840 (12.3 %) <0.001
50 to 64 years 26,347 (28.8 %) 12,344 (23.8 %) 14,003 (35.5 %)
65 to 79 years 35,693 (39.0 %) 21,435 (41.3 %) 14,258 (36.1 %)
80+ years 21,361 (23.4 %) 14,983 (28.8 %) 6378 (16.2 %)
Gender Male 43,981 (48.1 %) 23,053 (44.4 %) 20,928 (53.0 %) <0.001
Female 47,435 (51.9 %) 28,884 (55.6 %) 18,551 (47.0 %)
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stage I, II, and III were 94.0 % (95 % CI: 93.6 to 94.5 %),
84.6 % (95 % CI: 84.1 to 85.3 %), and 63.6 % (95 % CI:
62.8 to 64.5 %) compared to 91.7 % (95%CI: 91.1 to
92.3 %), 80.1 % (95 % CI: 79.3 to 80.9 %), and 64.6 % (95 %
CI: 63.7 to 65.6 %) in left-sided carcinomas (Fig. 3).
Discussion
Currently, data regarding the prognosis of right-sided
versus left-sided colon cancer are conflicting, however,
most studies revealed a poorer survival in right-sided
primary tumor location [14–18, 29].
To our knowledge this is the first population-based,
propensity score adjusted analysis investigating the prog-
nostic impact of tumor location in non-metastatic colon
cancer patients. Being aware of the conflicting data and
also of the challenges to handle relevant bias due to sub-
stantial imbalances regarding baseline characteristics be-
tween right- and left-sided colon cancer patients, we
have intentionally selected the propensity score match-
ing as a further statistical method in addition to com-
mon multivariate analysis to minimize confounding. In
the present analysis, the cohort was partitioned into sub-
groups containing one or more patients with right-sided
colon cancer who were matched to one or more patients
with left-sided colon cancer with similar values on the
observed covariates in the risk set (bipartite matching).
Hence, the main difference between the compared
groups in propensity-score matching was the location of
the colon cancer (left versus right). The advantage of the
propensity score adjusted analysis over multivariate ana-
lysis becomes evident from varying results in our study,
showing that multivariate analysis is obviously limited in
adjusting factors in large retrospective population-based
studies.
Based on a large collective of 91,416 patients with
stage I - III colon cancer diagnosed between 2004 and
2012, this is the first study providing evidence that the
prognosis of patients with right-sided colon cancer in
the overall population of stage I – III is similar or even
better after adjusting for a strong bias regarding various
patient and tumor characteristics by the use of
propensity score matching. We thus conclude that the
differences in the prognosis between right-sided and
left-sided colon cancer patients described in the
scientific literature are not real but caused by differences
regarding confounders that could not be completely
adjusted for in multivariate regression analysis.
Our results differ from the findings published by
Weiss et al. [19] demonstrating no 5-year overall sur-
vival difference between right- and left-sided colon can-
cer after adjusting for multiple variables. Weiss et al.
[19] analyzed 53,801 colon cancer patients aged 65 years
and older from the linked SEER-Medicare database
between 1992 and 2005. Interestingly, they found that
stage II right-sided colon cancer had lower mortality
compared to patients with a left-sided tumor (HR 0.92;
95 % CI, 0.87–0.97, P = 0.001), while stage III right-sided
colon cancer patients had higher mortality than those
with left-sided colon cancer (HR, 1.12; 95 % CI, 1.06 to
1.18; P < 0.001) [19]. The present analysis differs from
the study by Weiss and colleagues [19] regarding several
issues: First, in our investigation patients were included
if older than 18 years of age. The majority of patients
with colon cancer are usually older persons, however,
37.4 % of all patients in our analysis were younger than
64 years. In our opinion it is key to include younger
colon cancer patients as this is a subgroup, which has
been shown to dramatically increase in the past decade
[30]. Second, we used more recent data from 2004 to
2012 as opposed to the study by Weiss and colleagues
(1992–2005) [19]. Finally, while the investigation by
Weiss et al. [19] exclusively used conventional
multivariable analysis to adjust for imbalances between
patients with right - versus left-sided colon cancer, the
present investigation used propensity score matching as
an additional statistical tool in addition to multivariable
analyses.
One limitation of the present study is the lack of infor-
mation regarding microsatellite instability (MSI) in the
SEER database. According to the literature, colon cancer
with MSI have a better prognosis [31, 32]. Furthermore,
the frequency of MSI is different between right- and left-
Table 1 Patient characteristics (Continued)
Ethnicity Caucasian 72,937 (79.8 %) 42,296 (81.4 %) 30,641 (77.6 %) <0.001
African-American 10,572 (11.6 %) 6286 (12.1 %) 4286 (10.9 %)
Other/Unknown 7907 (8.6 %) 3355 (6.5 %) 4552 (11.5 %)
Marital status Married 49,901 (54.6 %) 27,219 (52.4 %) 22,682 (57.5 %) <0.001
Single 11,581 (12.7 %) 6120 (11.8 %) 5461 (13.8 %)
Widowed 17,770 (19.4 %) 11,835 (22.8 %) 5935 (15.0 %)
Other/Unknown 12,164 (13.3 %) 6763 (13.0 %) 5401 (13.7 %)
All data shown as n (%)
AJCC, American Joint Committee on Cancer, T-stage tumor stage, CEA Carcinoembryonic antigen
aChi-Square test
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sided colon cancers and differs also between different
tumor stages. One study estimated that the rate of
MSI-positive stage II right-sided colon cancers is
25 %, compared to less than 15 % in stage III right-
sided cancers [33]. Weiss et al. [19] argued that this dif-
ference might contribute to their results showing better
prognosis of stage II right-sided cancers. Unfortunately,
data on sporadic mismatch repair deficiency, germeline-
mutation prompted Lynch Syndrom, BRAF/KRAS/NRAS
mutations, or any family history can not be ascertained
from the SEER data. Hence, the fraction of patients with
these specific subtypes of colon cancer – which are known
to vary between the left and right colon side [13] - are
unknown in the present study. However, due to the
population-based nature of this analysis that mirrors the
real US population with colon cancer, the lack of this in-
formation does not impact our results, albeit limits the ex-
tent of interpretation of our data.
Fig. 2 Kaplan-Meier curves for overall and cancer-specific survival. Panel (a and b) depict the overall and cancer-specific survival in the original
data set and panel (c and d) the overall and cancer-specific survival after propensity score matching. The number of colon cancer patients at risk
are given below each plot
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Table 2 Prognostic factors for overall and cancer-specific mortality
Cox regression for overall survival Cox regression for cancer-specific survival
Unadjusteda Adjustedb Unadjusteda Adjustedb
HR (95 % CI) pc HR (95 % CI) pc HR (95 % CI) pc HR (95 % CI) pc
Cancer side Left-sided Reference <0.001 Reference 0.002 Reference <0.001 Reference 0.156
Right-sided 1.32 (1.29–1.36) 1.05 (1.02–1.09) 1.23 (1.19–1.27) 1.03 (0.99–1.08)
Tumor stage Stage I Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
(AJCC 6th ed.) Stage II 1.65 (1.59–1.71) 1.40 (1.35–1.45) 3.00 (2.81–3.20) 2.47 (2.31–2.65)
Stage III 2.34 (2.26–2.42) 2.30 (2.22–2.39) 6.41 (6.02–6.81) 5.79 (5.42–6.18)
Number of retrieved <12 Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
Regional lymph 12–16 0.90 (0.87–0.92) 0.82 (0.79–0.84) 0.92 (0.88–0.96) 0.78 (0.75–0.82)
Nodes 17+ 0.75 (0.73–0.77) 0.69 (0.67–0.72) 0.81 (0.78–0.84) 0.66 (0.64–0.69)
Grading G1 Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
G2 1.20 (1.14–1.26) 1.05 (1.00–1.10) 1.46 (1.36–1.56) 1.10 (1.03–1.18)
G3 1.76 (1.67–1.85) 1.28 (1.21–1.35) 2.60 (2.41–2.81) 1.51 (1.40–1.64)
G4 2.02 (1.83–2.22) 1.50 (1.36–1.66) 2.88 (2.53–3.27) 1.69 (1.49–1.93)
Unknown 0.91 (0.84–1.00) 1.04 (0.95–1.14) 1.03 (0.91–1.18) 1.20 (1.06–1.37)
Histology Adenocarcinoma Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
Adenocarcinoma in adenomatous polyp 0.53 (0.50–0.56) 0.80 (0.76–0.86) 0.36 (0.33–0.40) 0.71 (0.64–0.79)
Adenocarcinoma in villous adenoma 0.77 (0.71–0.83) 0.93 (0.86–1.01) 0.62 (0.55–0.70) 0.92 (0.82–1.03)
Adenocarcinoma in tubulovillous adenoma 0.63 (0.60–0.67) 0.84 (0.80–0.89) 0.44 (0.40–0.47) 0.73 (0.67–0.79)
Mucinous carcinoma 1.12 (1.08–1.17) 1.03 (0.99–1.07) 1.14 (1.08–1.20) 1.05 (0.99–1.10)
CEA C0-stage Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
C1-stage 1.91 (1.84–1.97) 1.61 (1.56–1.67) 2.29 (2.19–2.40) 1.79 (1.71–1.87)
Unknown/Borderline 1.42 (1.38–1.46) 1.37 (1.33–1.41) 1.49 (1.43–1.55) 1.48 (1.42–1.54)
Operation Segmental resection Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
Hemi/subtotal colectomy 1.27 (1.24–1.30) 1.08 (1.05–1.12) 1.26 (1.22–1.31) 1.11 (1.06–1.16)
Other 1.32 (1.18–1.48) 1.34 (1.19–1.50) 1.66 (1.44–1.91) 1.57 (1.36–1.81)
Year 2004 to 2006 Reference <0.001 Reference 0.258 Reference <0.001 Reference 0.542
2007 to 2009 0.93 (0.91–0.96) 1.02 (0.99–1.05) 0.93 (0.89–0.96) 1.02 (0.98–1.06)
2010 to 2012 0.87 (0.83–0.90) 0.98 (0.94–1.03) 0.87 (0.83–0.92) 0.99 (0.94–1.05)
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Table 2 Prognostic factors for overall and cancer-specific mortality (Continued)
Age Up to 49 years Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
50 to 64 years 1.14 (1.07–1.22) 1.20 (1.12–1.28) 0.94 (0.87–1.01) 1.04 (0.97–1.13)
65 to 79 years 2.18 (2.05–2.33) 2.30 (2.15–2.45) 1.37 (1.28–1.47) 1.57 (1.45–1.69)
80+ years 5.15 (4.83–5.49) 5.10 (4.77–5.45) 2.69 (2.50–2.89) 2.88 (2.66–3.11)
Gender male Reference 0.614 Reference <0.001 Reference 0.001 Reference <0.001
female 1.01 (0.98–1.03) 0.75 (0.73–0.77) 1.06 (1.02–1.09) 0.84 (0.81–0.87)
Ethnicity Caucasian Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
African-American 1.03 (0.99–1.07) 1.17 (1.13–1.22) 1.19 (1.13–1.25) 1.24 (1.18–1.30)
Other/Unknown 0.70 (0.67–0.74) 0.77 (0.73–0.81) 0.81 (0.76–0.87) 0.83 (0.78–0.89)
Marital status Married Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
Single 1.32 (1.27–1.37) 1.46 (1.40–1.52) 1.40 (1.33–1.47) 1.41 (1.33–1.48)
Widowed 2.21 (2.15–2.28) 1.42 (1.37–1.46) 1.91 (1.84–1.99) 1.34 (1.28–1.40)
Other/Unknown 1.25 (1.20–1.30) 1.28 (1.23–1.33) 1.21 (1.15–1.28) 1.19 (1.13–1.26)
Hazard ratios (HR) with 95 % confidence intervals (Wald type)
The number of positive regional lymph nodes and T-stage were excluded from analysis to avoid collinearity with stage
AJCC American Joint Committee on Cancer, CEA Carcinoembryonic antigen
aUnivariate Cox regression analysis, bmultivariable Cox regression analysis full model, clikelihood ratio tests
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Table 3 Imbalances of baseline characteristics between right- and left-sided colon cancer patients
Logistic regression in raw data (N = 91,4166)a Patient characteristics after stratified bipartite propensity score matching (N = 90,067)c
OR (95 % CI) Pb Total Right-sided carcinoma Left-sided carcinoma Pb
N = 90,067 N = 51,331 N = 38,736
Tumor stage Stage I D) 24,924 (27.7 %) 13,622 (26.5 %) 11,302 (29.2 %) E)
(AJCC 6th ed.) Stage II 33,002 (36.6 %) 19,790 (38.6 %) 13,212 (34.1 %)
Stage III 32,141 (35.7 %) 17,919 (34.9 %) 14,222 (36.7 %)
T-stage T1 Reference <0.001 11387.4 (12.6 %) 6378 (12.4 %) 5009.4 (12.9 %) 0.908
T2 1.45 (1.36–1.55) 17213.6 (19.1 %) 9360 (18.2 %) 7853.6 (20.3 %)
T3 1.15 (1.08–1.22) 50984.6 (56.6 %) 29,704 (57.9 %) 21280.6 (54.9 %)
T4 1.08 (1.00–1.17) 10481.4 (11.6 %) 5889 (11.5 %) 4592.4 (11.9 %)
Number of positive 0 Reference <0.001 57,926 (64.3 %) 33,412 (65.1 %) 24,514 (63.3 %) 0.733
Regional lymph 1 0.82 (0.78–0.87) 10303.2 (11.4 %) 5579 (10.9 %) 4724.2 (12.2 %)
Nodes 2–3 0.82 (0.77–0.86) 9909.2 (11.0 %) 5631 (11.0 %) 4278.2 (11.0 %)
4–6 0.87 (0.81–0.93) 6433.9 (7.1 %) 3650 (7.1 %) 2783.9 (7.2 %)
7+ 0.94 (0.86–1.01) 5494.7 (6.1 %) 3059 (6.0 %) 2435.7 (6.3 %)
Number of retrieved <12 Reference <0.001 18327.7 (20.3 %) 10,240 (19.9 %) 8087.7 (20.9 %) 0.931
Regional lymph 12–16 1.72 (1.64–1.80) 25,713 (28.5 %) 14,813 (28.9 %) 10,900 (28.1 %)
Nodes 17+ 2.44 (2.33–2.55) 46026.3 (51.1 %) 26,278 (51.2 %) 19748.3 (51.0 %)
Grading G1 Reference <0.001 8274.1 (9.2 %) 4667 (9.1 %) 3607.1 (9.3 %) 0.954
G2 0.97 (0.91–1.02) 60851.4 (67.6 %) 34,630 (67.5 %) 26221.4 (67.7 %)
G3 1.74 (1.62–1.87) 16543.4 (18.4 %) 9599 (18.7 %) 6944.4 (17.9 %)
G4 1.92 (1.64–2.24) 1738.2 (1.9 %) 1035 (2.0 %) 703.2 (1.8 %)
Unknown 0.92 (0.82–1.03) 2659.8 (3.0 %) 1400 (2.7 %) 1259.8 (3.3 %)
Histology Adenocarcinoma Reference <0.001 62172.7 (69.0 %) 35,607 (69.4 %) 26565.7 (68.6 %) 0.978
Adeno-Ca in adenomatous polyp 0.95 (0.89–1.02) 5139.1 (5.7 %) 2883 (5.6 %) 2256.1 (5.8 %)
Adeno-Ca in villous adenoma 2.02 (1.82–2.25) 2901.7 (3.2 %) 1664 (3.2 %) 1237.7 (3.2 %)
Adeno-Ca in tubulovillous adenoma 1.73 (1.62–1.85) 8333.5 (9.3 %) 4806 (9.4 %) 3527.5 (9.1 %)
Mucinous carcinoma 2.23 (2.10–2.37) 11,520 (12.8 %) 6371 (12.4 %) 5149 (13.3 %)
CEA C0-stage Reference <0.001 31640.5 (35.1 %) 18,476 (36.0 %) 13164.5 (34.0 %) 0.763
C1-stage 0.88 (0.83–0.92) 17236.6 (19.1 %) 9804 (19.1 %) 7432.6 (19.2 %)
Unknown/Borderline 1.00 (0.96–1.04) 41189.8 (45.7 %) 23,051 (44.9 %) 18138.8 (46.8 %)
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Table 3 Imbalances of baseline characteristics between right- and left-sided colon cancer patients (Continued)
Operation Segmental resection Reference <0.001 13557.3 (15.1 %) 7750 (15.1 %) 5807.3 (15.0 %) 0.447
Hemi/subtotal colectomy 14.3 (13.8–14.8) 75781.8 (84.1 %) 43,171 (84.1 %) 32610.8 (84.2 %)
Other 2.66 (2.32–3.05) 727.9 (0.8 %) 410 (0.8 %) 317.9 (0.8 %)
Year 2004 to 2006 Reference 0.285 31,052 (34.5 %) 17,527 (34.1 %) 13,525 (34.9 %) E)
2007 to 2009 0.97 (0.93–1.01) 30,869 (34.3 %) 17,585 (34.3 %) 13,284 (34.3 %)
2010 to 2012 0.97 (0.93–1.01) 28,146 (31.3 %) 16,219 (31.6 %) 11,927 (30.8 %)
Age Up to 49 years Reference <0.001 5545.6 (6.2 %) 3174 (6.2 %) 2371.6 (6.1 %) 0.995
50 to 64 years 1.56 (1.46–1.66) 21581.8 (24.0 %) 12,332 (24.0 %) 9249.8 (23.9 %)
65 to 79 years 2.65 (2.49–2.83) 37577.3 (41.7 %) 21,253 (41.4 %) 16324.3 (42.1 %)
80+ years 4.08 (3.80–4.39) 25362.3 (28.2 %) 14,572 (28.4 %) 10790.3 (27.9 %)
Gender male Reference <0.001 40730.6 (45.2 %) 22,954 (44.7 %) 17776.6 (45.9 %) 0.570
female 1.30 (1.26–1.35) 49336.4 (54.8 %) 28,377 (55.3 %) 20959.4 (54.1 %)
Ethnicity Caucasian Reference <0.001 72714.5 (80.7 %) 41,771 (81.4 %) 30943.5 (79.9 %) 0.050
African-American 1.09 (1.04–1.15) 11763.1 (13.1 %) 6213 (12.1 %) 5550.1 (14.3 %)
Other/Unknown 0.66 (0.62–0.70) 5589.4 (6.2 %) 3347 (6.5 %) 2242.4 (5.8 %)
Marital status Married Reference 0.877 47284.7 (52.5 %) 27,005 (52.6 %) 20279.7 (52.4 %) 0.930
Single 0.98 (0.93–1.03) 10609.8 (11.8 %) 6044 (11.8 %) 4565.8 (11.8 %)
Widowed 1.00 (0.95–1.05) 20331.9 (22.6 %) 11,580 (22.6 %) 8751.9 (22.6 %)
Other/Unknown 0.99 (0.94–1.05) 11840.6 (13.1 %) 6702 (13.1 %) 5138.6 (13.3 %)
aMultivariable logistic regression with the odds ratio (OR) for right-sided carcinomas in the original raw data set (N = 91,416)
AJCC American Joint Committee on Cancer, T-stage tumor stage, CEA Carcinoembryonic antigen
bLikelihood ratio tests
cAfter full bipartite propensity score matching with stratification for year of diagnosis and tumor stage, a multivariable conditional logistic regression based on the subgroups obtained by the matching procedure was
performed. No significant bias was observed for cancer side
1349 patients were excluded because of lacking counterpart in the other group
Weighted matching causes decimals for the number of patients in the group with left-sided cancer
D)Excluded to avoid collinearity with the number of positive regional lymph nodes
E)No statistical test because propensity score matching was stratified for year of diagnosis and tumor stage
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Fig. 3 Kaplan-Meier curves for overall and cancer-specific survival after stratified propensity score matching. Panels (a, c, and e) depict the overall
survival and panels (b, d, and f) depict the cancer-specific survival for stage I (panels a and b), stage II (panels c and d), and stage III (panels e and f).
The number of colon cancer patients at risk are given below each plot
Warschkow et al. BMC Cancer  (2016) 16:554 Page 12 of 14
Overall, the existing literature shows conflicting data
regarding prognosis in right-sided vs. left-sided colon
cancer. It is difficult to compare the available studies
due to various differences, e.g. in study design and inclu-
sion and exclusion criteria. Suboptimal adjusting of con-
founders seems to be the major difficulty to obtain a
thorough analysis regarding the prognostic impact of
tumor location, pointing out the strength of our study
with further adjustment by propensity score matching.
Our investigation provides evidence that right-sided
tumour location itself is associated with improved prog-
nosis compared to the left-sided colon cancer, mostly
due to better prognosis in stage I and stage II patients.
We would like to acknowledge the limitations of the
present study. First, information regarding chemothera-
peutic treatments of patients can not be ascertained
from the SEER data. Second, information on comorbidi-
ties, performance status and data regarding family his-
tory are also not available in the SEER database. To
which extent these parameters might have influenced
the analysis remains unclear. Third, while we did risk-
adjust for known confounders, potential bias due to un-
known confounding cannot be excluded. Unobserved
confounders represent a relevant limitation to the
generalizability of the propensity score method. Finally,
although propensity-score adjustment represents an add-
itional, valuable statistical tool used in the present ana-
lyses, the results must be interpreted with some caution
due to a fraction of unmatched patients.
Conclusions
This population-based propensity score adjusted analysis
on stage I - III colon cancer provides evidence that the
prognosis of patients with right-sided colon cancer is
better compared to left-sided colon cancer mostly due to
a better survival in stage I and stage II patients. This
finding questions the paradigm of worse survival in
right-sided colon cancer patients claimed by the majority
of previous research.
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